Rezolute, Inc. (RZLT) Stock Score, Valuation & Financial Research

Rezolute, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for RZLT

Rezolute, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.10. These figures are a research snapshot, not a buy or sell recommendation.

What Rezolute, Inc. does

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Rezolute, Inc. is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model focuses on the research and development of therapeutic candidates for rare diseases, specifically hyperinsulinism, and it relies on capital raises and equity financing to fund its ongoing clinical trials and operational expenses.

Products and services

  • The company is developing ersodetug, a therapeutic candidate designed to treat refractory hypoglycemia caused by various forms of hyperinsulinism.

Brands and product families

  • Ersodetug — Lead clinical-stage therapeutic candidate for hyperinsulinism. Source

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct and manage its clinical trials. Source

Business relationships and partnerships

  • Handok, Inc. — Strategic investor and partner involved in securities purchase agreements and private placements to support the company's capital requirements. Source

Business strengths to evaluate

  • Clinical development pipeline focused on ultra-rare disease indications Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Clinical trial failure or delays in regulatory approval Source

Sources: Company research source · Handok, Inc.

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

RZLT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.10
Market capitalization:
394.47M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -77.59M
Free cash flow:
USD -64.64M
Cash:
USD 10.62M
Total debt:
USD 934K
EPS:
USD -0.76

What stands out

  • Free cash flow is USD -64.64M, negative for the stored period.
  • The balance sheet shows USD 10.62M of cash versus USD 934K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for RZLT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can RZLT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is RZLT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for RZLT to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of RZLT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research RZLT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.